Forth Marc

SEC source: 0001104659-26-076511 · tm2618486-3_4seq1.xml · nonDerivative · entry 1

Forth Marc · CIK 0001816988 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 973,231

F1 · security: Represents an award of restricted stock units ("RSUs") granted on June 17, 2026 (the "Grant Date"). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.

F1 · price: Represents an award of restricted stock units ("RSUs") granted on June 17, 2026 (the "Grant Date"). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.

SEC source: 0001610717-25-000134 · form4.xml · derivative · entry 1

Forth Marc · CIK 0001816988 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 370,370

Underlying: Class A Common Stock · 370,370 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") will be settled in cash based on the fair market value of the Issuer's Class A Common Stock on the applicable vesting date.

F2 · derivative.exercise_date: 1/3rd of the RSUs shall vest on each anniversary of May 21, 2025.

F2 · derivative.expiration_date: 1/3rd of the RSUs shall vest on each anniversary of May 21, 2025.

SEC source: 0001104659-24-097067 · tm2423415-3_4seq1.xml · derivative · entry 2

Forth Marc · CIK 0001816988 · Director · CHIEF EXECTUIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,256,062

Underlying: Class A Common Stock · 1,256,062 shares

Expires 2034-08-30

F3 · shares: Represents an award of stock options granted on August 31, 2024 (the "Grant Date"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date.

F3 · derivative.exercise_date: Represents an award of stock options granted on August 31, 2024 (the "Grant Date"), which vest and become exercisable in substantially equal monthly installments over the eighteen months following the Grant Date, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001104659-24-097067 · tm2423415-3_4seq1.xml · nonDerivative · entry 1

Forth Marc · CIK 0001816988 · Director · CHIEF EXECTUIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 750,547

F1 · price: Represents an award of restricted stock units granted on August 31, 2024 (the "Grant Date"), which vests in full on the second anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date.

F2 · balance_after: Includes an award of restricted stock units ("RSUs") in the amount of 279,855 previously granted on April 26, 2023, which were previously reported on July 24, 2023 as derivative securities in Table II due to a clerical error, and which are now being reported as common stock in Table I. The vesting terms for the RSUs have not changed from what was previously reported on July 24, 2023.

SEC source: 0001104659-24-037438 · tm249503-5_4seq1.xml · derivative · entry 1

Forth Marc · CIK 0001816988 · Director · CHIEF EXECTUIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 212,466

Underlying: Common Stock · 212,466 shares

Expires 2034-03-18

F1 · shares: Represents an award of stock options granted on March 19, 2024 (the "Grant Date"), which vests in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date.

F1 · derivative.exercise_date: Represents an award of stock options granted on March 19, 2024 (the "Grant Date"), which vests in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001104659-23-083566 · tm2321918-9_4seq1.xml · derivative · entry 6

Forth Marc · CIK 0001816988 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 279,855

Underlying: Common Stock · 279,855 shares

Expires not disclosed

F8 · derivative.exercise_price: At the Effective Time, each outstanding award of restricted stock unit ("RSU") representing the contingent right to receive shares of AEON common stock (each an "AEON RSU") was automatically cancelled and converted into an RSU representing the contingent right to receive a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON RSU multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share.

F1 · shares: On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. ("Merger Sub") and AEON Biopharma, Inc. ("AEON"), upon consummation of the transactions contemplated thereby (the "Effective Time"), each issued and outstanding share of common stock of AEON ("AEON common stock") was automatically cancelled and converted into approximately 2.328 (the "Exchange Ratio") shares of Class A common stock of the Issuer.

F8 · shares: At the Effective Time, each outstanding award of restricted stock unit ("RSU") representing the contingent right to receive shares of AEON common stock (each an "AEON RSU") was automatically cancelled and converted into an RSU representing the contingent right to receive a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON RSU multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share.

F9 · shares: Represents an award of RSUs on April 26, 2023, which vests in four yearly installments from April 26, 2023, subject to the reporting person's continued service through the applicable vesting date.

F1 · price: On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. ("Merger Sub") and AEON Biopharma, Inc. ("AEON"), upon consummation of the transactions contemplated thereby (the "Effective Time"), each issued and outstanding share of common stock of AEON ("AEON common stock") was automatically cancelled and converted into approximately 2.328 (the "Exchange Ratio") shares of Class A common stock of the Issuer.

F9 · derivative.exercise_date: Represents an award of RSUs on April 26, 2023, which vests in four yearly installments from April 26, 2023, subject to the reporting person's continued service through the applicable vesting date.

F9 · derivative.expiration_date: Represents an award of RSUs on April 26, 2023, which vests in four yearly installments from April 26, 2023, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001104659-23-083566 · tm2321918-9_4seq1.xml · derivative · entry 5

Forth Marc · CIK 0001816988 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 194,118

Underlying: Common Stock · 194,118 shares

Expires 2032-03-09

F1 · shares: On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. ("Merger Sub") and AEON Biopharma, Inc. ("AEON"), upon consummation of the transactions contemplated thereby (the "Effective Time"), each issued and outstanding share of common stock of AEON ("AEON common stock") was automatically cancelled and converted into approximately 2.328 (the "Exchange Ratio") shares of Class A common stock of the Issuer.

F2 · shares: At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an "AEON Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share.

F7 · shares: Represents an award of stock options on March 9, 2022, which vests in four yearly installments from March 9, 2022, subject to the reporting person's continued service through the applicable vesting date.

F1 · price: On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. ("Merger Sub") and AEON Biopharma, Inc. ("AEON"), upon consummation of the transactions contemplated thereby (the "Effective Time"), each issued and outstanding share of common stock of AEON ("AEON common stock") was automatically cancelled and converted into approximately 2.328 (the "Exchange Ratio") shares of Class A common stock of the Issuer.

F7 · derivative.exercise_date: Represents an award of stock options on March 9, 2022, which vests in four yearly installments from March 9, 2022, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001104659-23-083566 · tm2321918-9_4seq1.xml · derivative · entry 4

Forth Marc · CIK 0001816988 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 381,480

Underlying: Common Stock · 381,480 shares

Expires 2032-03-09

F1 · shares: On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. ("Merger Sub") and AEON Biopharma, Inc. ("AEON"), upon consummation of the transactions contemplated thereby (the "Effective Time"), each issued and outstanding share of common stock of AEON ("AEON common stock") was automatically cancelled and converted into approximately 2.328 (the "Exchange Ratio") shares of Class A common stock of the Issuer.

F2 · shares: At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an "AEON Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share.

F6 · shares: Represents an award of stock options on March 9, 2022, which vests in four yearly installments from March 9, 2022, subject to the reporting person's continued service through the applicable vesting date.

F1 · price: On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. ("Merger Sub") and AEON Biopharma, Inc. ("AEON"), upon consummation of the transactions contemplated thereby (the "Effective Time"), each issued and outstanding share of common stock of AEON ("AEON common stock") was automatically cancelled and converted into approximately 2.328 (the "Exchange Ratio") shares of Class A common stock of the Issuer.

F6 · derivative.exercise_date: Represents an award of stock options on March 9, 2022, which vests in four yearly installments from March 9, 2022, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001104659-23-083566 · tm2321918-9_4seq1.xml · derivative · entry 3

Forth Marc · CIK 0001816988 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 291,332

Underlying: Common Stock · 291,332 shares

Expires 2031-09-09

F1 · shares: On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. ("Merger Sub") and AEON Biopharma, Inc. ("AEON"), upon consummation of the transactions contemplated thereby (the "Effective Time"), each issued and outstanding share of common stock of AEON ("AEON common stock") was automatically cancelled and converted into approximately 2.328 (the "Exchange Ratio") shares of Class A common stock of the Issuer.

F2 · shares: At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an "AEON Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share.

F5 · shares: Represents an award of stock options on September 9, 2021, which vests in four yearly installments from March 5, 2021, subject to the reporting person's continued service through the applicable vesting date.

F1 · price: On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. ("Merger Sub") and AEON Biopharma, Inc. ("AEON"), upon consummation of the transactions contemplated thereby (the "Effective Time"), each issued and outstanding share of common stock of AEON ("AEON common stock") was automatically cancelled and converted into approximately 2.328 (the "Exchange Ratio") shares of Class A common stock of the Issuer.

F5 · derivative.exercise_date: Represents an award of stock options on September 9, 2021, which vests in four yearly installments from March 5, 2021, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001104659-23-083566 · tm2321918-9_4seq1.xml · derivative · entry 2

Forth Marc · CIK 0001816988 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 324,021

Underlying: Common Stock · 324,021 shares

Expires 2030-08-05

F1 · shares: On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. ("Merger Sub") and AEON Biopharma, Inc. ("AEON"), upon consummation of the transactions contemplated thereby (the "Effective Time"), each issued and outstanding share of common stock of AEON ("AEON common stock") was automatically cancelled and converted into approximately 2.328 (the "Exchange Ratio") shares of Class A common stock of the Issuer.

F2 · shares: At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an "AEON Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share.

F4 · shares: Represents an award of stock options on August 5, 2020, which vests in four yearly installments from July 1, 2020, subject to the reporting person's continued service through the applicable vesting date.

F1 · price: On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. ("Merger Sub") and AEON Biopharma, Inc. ("AEON"), upon consummation of the transactions contemplated thereby (the "Effective Time"), each issued and outstanding share of common stock of AEON ("AEON common stock") was automatically cancelled and converted into approximately 2.328 (the "Exchange Ratio") shares of Class A common stock of the Issuer.

F4 · derivative.exercise_date: Represents an award of stock options on August 5, 2020, which vests in four yearly installments from July 1, 2020, subject to the reporting person's continued service through the applicable vesting date.

SEC source: 0001104659-23-083566 · tm2321918-9_4seq1.xml · derivative · entry 1

Forth Marc · CIK 0001816988 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 970,588

Underlying: Common Stock · 970,588 shares

Expires 2029-11-20

F1 · shares: On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. ("Merger Sub") and AEON Biopharma, Inc. ("AEON"), upon consummation of the transactions contemplated thereby (the "Effective Time"), each issued and outstanding share of common stock of AEON ("AEON common stock") was automatically cancelled and converted into approximately 2.328 (the "Exchange Ratio") shares of Class A common stock of the Issuer.

F2 · shares: At the Effective Time, each outstanding option to purchase shares of AEON common stock (each an "AEON Option") was automatically cancelled and converted into an option to purchase a number of shares of common stock of the Issuer equal to (i) the number of shares of AEON common stock subject to the applicable AEON Option multipled by (ii) the Exchange Ratio, rounded down to the nearest whole share.

F3 · shares: Represents an award of stock options on November 20, 2019, which vests in four yearly installments from June 11, 2019, subject to the reporting person's continued service through the applicable vesting date.

F1 · price: On July 21, 2023, pursuant to that certain Business Combination Agreement, dated as of December 12, 2022, as amended April 27, 2023, by and among the Issuer, Priveterra Merger Sub, Inc. ("Merger Sub") and AEON Biopharma, Inc. ("AEON"), upon consummation of the transactions contemplated thereby (the "Effective Time"), each issued and outstanding share of common stock of AEON ("AEON common stock") was automatically cancelled and converted into approximately 2.328 (the "Exchange Ratio") shares of Class A common stock of the Issuer.

F3 · derivative.exercise_date: Represents an award of stock options on November 20, 2019, which vests in four yearly installments from June 11, 2019, subject to the reporting person's continued service through the applicable vesting date.